Fig. 13

TMB. In the TCGA, the level of TMB was significantly negatively correlated with the risk score (A), and an increased level of TMB correlated with improved OS (P < 0.001) (B). These results were consistent with the results obtained from IMvigor210 (C-D). Moreover, in the IMvigor210 cohort, low-risk patients had more significant immunotherapy effects (PD-1 blockade therapy) (E). TMB, tumor mutation burden; TCGA, The Cancer Genome Atlas; OS, overall survival; CR, complete response, PR, partial response, SD, stable disease; PD, progressive disease